Antidiabetic Biguanides Market

Antidiabetic Biguanides Market contains market size and forecasts of Antidiabetic Biguanides in global, including the following market information:

• Global Antidiabetic Biguanides Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global Antidiabetic Biguanides Market Sales, 2017-2022, 2023-2028, (K Pcs)
• Global top five Antidiabetic Biguanides companies in 2021 (%)

The global Antidiabetic Biguanides market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Metformin IR Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Antidiabetic Biguanides include Pfizer, AstraZeneca, GlaxoSmithKline, Merck & Co, Eli Lilly, Sanofi, Takeda Pharmaceuticals, Novo Nordisk and Servier Laboratories, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Antidiabetic Biguanides manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Antidiabetic Biguanides Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)

Global Antidiabetic Biguanides Market Segment Percentages, by Type, 2021 (%)

• Metformin IR
• Metformin SR

Global Antidiabetic Biguanides Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)

Global Antidiabetic Biguanides Market Segment Percentages, by Application, 2021 (%)

• Hospitals
• Clinics
• Other

Global Antidiabetic Biguanides Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)

Global Antidiabetic Biguanides Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Antidiabetic Biguanides revenues in global market, 2017-2022 (Estimated), ($ millions)
• Key companies Antidiabetic Biguanides revenues share in global market, 2021 (%)
• Key companies Antidiabetic Biguanides sales in global market, 2017-2022 (Estimated), (K Pcs)
• Key companies Antidiabetic Biguanides sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Pfizer
• AstraZeneca
• GlaxoSmithKline
• Merck & Co
• Eli Lilly
• Sanofi
• Takeda Pharmaceuticals
• Novo Nordisk
• Servier Laboratories
• Boehringer Ingelheim
• Bristol-Myers Squibb